Pharmaceutical

Opinion: STAT+: Preventive drugs may be the best soluti...

Preventive biologics can address the anti-infectives market failure while simult...

Opinion: Listen: Why long Covid might predate the pandemic

This week on the "First Opinion Podcast": an entirely new way to think about lon...

STAT+: Revenue cycle management company Waystar files f...

Waystar, a revenue cycle management company, filed for an IPO Monday.

STAT+: It’s time for the FDA to halt Cassava Sciences’ ...

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studie...

Breast cancer is deadlier for Black women. A study of m...

Breast cancer is deadlier for Black women. A study of mammograms could help clos...

STAT+: When Medicare paid doctors differently, fewer pa...

Doctors lowered the incidence of heart disease and strokes among their patients ...

Rankings

Antiverse and GlobalBio extend checkpoint inhibitor col...

Antiverse and GlobalBio have extended their collaboration agreement to advance ...

AI startup Leucine raises $7m for drug manufacturing di...

Leucine is joining the artificial intelligence (AI) wave sweeping through the p...

Vaxcyte and Lonza sign new commercial manufacturing agr...

Vaxcyte has signed a new commercial agreement with Lonza for the global manufac...

Tagrisso plus chemo has FDA priority review for metasta...

The US Food and Drug Administration (FDA) has granted a priority review to the ...

MSD’s Keytruda expands reach in lung cancer with neoadj...

The United States Food and Drug Administration (FDA) has approved yet another c...

NorthSea Therapeutics bags FDA rare paediatric disease ...

Dutch biotech firm, NorthSea Therapeutics, has seen one of its treatments for n...

Spark Therapeutics partners with SpliceBio for gene the...

Spanish biotech SpliceBio has signed a licensing agreement with Spark Thera...

BioAegis scores $20m BARDA contract to develop ARDS the...

The US Biomedical Advanced Research and Development Authority (BARDA) has award...

Novo Nordisk stops trial of Ozempic in kidneys as inter...

On Tuesday 10 October, Novo Nordisk announced that its FLOW trial, which studie...